PDF(Pubmed)
Abstract：
OBJECTIVE: The aim of this study was to analyze the second-trimester levels of vitronectin and plasminogen activator inhibitor-1 in gestational diabetes mellitus.
METHODS: This study was conducted between September 2020 and December 2020 at the University of Health Sciences, Bursa Yuksek Ihtisas Research and Training Hospital, Department of Obstetrics and Gynecology. A total of 30 pregnant women with gestational diabetes mellitus and 60 healthy controls between 24 and 27/6 weeks of gestation were included. The inclusion criteria were as follows: being between 18 and 45 years old and 24-27/6 gestational weeks, having singleton pregnancy, diagnosed with gestational diabetes mellitus by using a two-step challenge test. The exclusion criteria of this study were as follows: chronic inflammatory or infectious disease, fasting blood glucose>126 mg/dL, intolerance to glucose tolerance testing, abnormal liver or kidney function tests, as well as pregnancy with pre-gestational diabetes history of adverse perinatal outcomes. Serum vitronectin and plasminogen activator inhibitor-1 levels were measured using the enzyme-linked immunosorbent assay method.
RESULTS: Vitronectin and plasminogen activator inhibitor-1 levels were higher in the gestational diabetes mellitus group compared with controls [91.85 (23.08) vs. 80.10 (39.18) ng/mL, for vitronectin and 6.50 (1.05) vs. 4.35(1.0) ng/mL, for plasminogen activator inhibitor-1 (for both p<0.001)]. vitronectin >84.7 ng/mL was found to predict gestational diabetes mellitus with a sensitivity of 70% and specificity of 63.3%. Moreover, vitronectin had a significant positive correlation with fasting blood glucose (r=0.476, p<0.001), postprandial blood glucose (r=0.489, p<0.001), HbA1c (r=0.713, p<0.001), and plasminogen activator inhibitor-1 (r=0.586, p<0.001).
CONCLUSIONS: This study revealed that second-trimester vitronectin and plasminogen activator inhibitor-1 are increased in gestational diabetes mellitus and vitronectin could be a candidate for the prediction of gestational diabetes mellitus.
METHODS: This study was conducted between September 2020 and December 2020 at the University of Health Sciences, Bursa Yuksek Ihtisas Research and Training Hospital, Department of Obstetrics and Gynecology. A total of 30 pregnant women with gestational diabetes mellitus and 60 healthy controls between 24 and 27/6 weeks of gestation were included. The inclusion criteria were as follows: being between 18 and 45 years old and 24-27/6 gestational weeks, having singleton pregnancy, diagnosed with gestational diabetes mellitus by using a two-step challenge test. The exclusion criteria of this study were as follows: chronic inflammatory or infectious disease, fasting blood glucose>126 mg/dL, intolerance to glucose tolerance testing, abnormal liver or kidney function tests, as well as pregnancy with pre-gestational diabetes history of adverse perinatal outcomes. Serum vitronectin and plasminogen activator inhibitor-1 levels were measured using the enzyme-linked immunosorbent assay method.
RESULTS: Vitronectin and plasminogen activator inhibitor-1 levels were higher in the gestational diabetes mellitus group compared with controls [91.85 (23.08) vs. 80.10 (39.18) ng/mL, for vitronectin and 6.50 (1.05) vs. 4.35(1.0) ng/mL, for plasminogen activator inhibitor-1 (for both p<0.001)]. vitronectin >84.7 ng/mL was found to predict gestational diabetes mellitus with a sensitivity of 70% and specificity of 63.3%. Moreover, vitronectin had a significant positive correlation with fasting blood glucose (r=0.476, p<0.001), postprandial blood glucose (r=0.489, p<0.001), HbA1c (r=0.713, p<0.001), and plasminogen activator inhibitor-1 (r=0.586, p<0.001).
CONCLUSIONS: This study revealed that second-trimester vitronectin and plasminogen activator inhibitor-1 are increased in gestational diabetes mellitus and vitronectin could be a candidate for the prediction of gestational diabetes mellitus.
摘要：
目的：本研究旨在分析妊娠糖尿病患者孕中期玻连蛋白和纤溶酶原激活物抑制剂-1的水平。
方法：这项研究于2020年9月至2020年12月在健康科学大学进行，布尔萨YuksekIhtisas研究和培训医院，妇产科。总共包括30名妊娠糖尿病孕妇和60名24至27/6周的健康对照。纳入标准如下：18至45岁，24-27/6孕周，单身怀孕，通过使用两步攻击测试诊断为妊娠期糖尿病。本研究的排除标准如下：慢性炎症或感染性疾病，空腹血糖>126mg/dL，对葡萄糖耐量测试不耐受，肝功能或肾功能异常，以及妊娠合并孕前糖尿病史的不良围产结局。使用酶联免疫吸附测定法测量血清玻连蛋白和纤溶酶原激活物抑制剂1水平。
结果：妊娠糖尿病组的玻连蛋白和纤溶酶原激活物抑制剂-1水平高于对照组[91.85（23.08）vs.80.10(39.18)ng/mL,玻连蛋白和6.50(1.05)vs.4.35(1.0)ng/mL,对于纤溶酶原激活物抑制剂-1（对于两者p<0.001）]。玻连蛋白>84.7ng/mL可预测妊娠期糖尿病,其敏感性为70%,特异性为63.3%.此外，玻连蛋白与空腹血糖呈显著正相关(r=0.476,p<0.001),餐后血糖（r=0.489，p<0.001），HbA1c（r=0.713，p<0.001），和纤溶酶原激活物抑制剂-1（r=0.586，p<0.001）。
结论：这项研究表明，妊娠糖尿病中的孕中期玻连蛋白和纤溶酶原激活物抑制剂-1升高，玻连蛋白可能是预测妊娠糖尿病的候选指标。
方法：这项研究于2020年9月至2020年12月在健康科学大学进行，布尔萨YuksekIhtisas研究和培训医院，妇产科。总共包括30名妊娠糖尿病孕妇和60名24至27/6周的健康对照。纳入标准如下：18至45岁，24-27/6孕周，单身怀孕，通过使用两步攻击测试诊断为妊娠期糖尿病。本研究的排除标准如下：慢性炎症或感染性疾病，空腹血糖>126mg/dL，对葡萄糖耐量测试不耐受，肝功能或肾功能异常，以及妊娠合并孕前糖尿病史的不良围产结局。使用酶联免疫吸附测定法测量血清玻连蛋白和纤溶酶原激活物抑制剂1水平。
结果：妊娠糖尿病组的玻连蛋白和纤溶酶原激活物抑制剂-1水平高于对照组[91.85（23.08）vs.80.10(39.18)ng/mL,玻连蛋白和6.50(1.05)vs.4.35(1.0)ng/mL,对于纤溶酶原激活物抑制剂-1（对于两者p<0.001）]。玻连蛋白>84.7ng/mL可预测妊娠期糖尿病,其敏感性为70%,特异性为63.3%.此外，玻连蛋白与空腹血糖呈显著正相关(r=0.476,p<0.001),餐后血糖（r=0.489，p<0.001），HbA1c（r=0.713，p<0.001），和纤溶酶原激活物抑制剂-1（r=0.586，p<0.001）。
结论：这项研究表明，妊娠糖尿病中的孕中期玻连蛋白和纤溶酶原激活物抑制剂-1升高，玻连蛋白可能是预测妊娠糖尿病的候选指标。
